1-3 . Microglia modulate pro-inflammatory and neurotoxic activities in astrocytes, but the mechanisms involved are not completely understood 4, 5 . Here we report that TGFα and VEGF-B produced by microglia regulate the pathogenic activities of astrocytes in the experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis. Microglia-derived TGFα acts via the ErbB1 receptor in astrocytes to limit their pathogenic activities and EAE development. Conversely, microglial VEGF-B triggers FLT-1 signalling in astrocytes and worsens EAE. VEGF-B and TGFα also participate in the microglial control of human astrocytes.
experiments with n = 9 mice per group. f, Heat map of 9,957 genes expressed in microglia from control and CX3CR1-AHR mice (n = 3 mice per group). Gene expression is row-centred and log 2 -transformed, and saturated at levels −0.5 and +0.5 for visualization satisfying a false discovery rate (FDR) <0.1. g, Microglial mRNA expression determined by qPCR in control (n = 5) and CX3CR1-AHR (n = 5) EAE mice. Data in a-d, g are mean ± s.e.m. P values were determined by two-way analysis of variance (ANOVA) (a) or two-sided Student's t-test (b-e, g).
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fused to an oestrogen ligand-binding domain 8 . After treatment of CX3CR1-AHR mice with tamoxifen, AHR-expressing peripheral CX3CR1
+ cells are replenished from the bone marrow while microglia remain AHR deficient without impaired survival (Extended Data Fig. 1a-d) . Microglial AHR deletion worsened EAE, increasing demyelination and CNS monocyte recruitment (Fig. 1a-c) ; the T-cell response was unaffected (Extended Data Fig. 1e, 
f). AHR deletion in peripheral CX3CR1
+ cells achieved by chronic tamoxifen administration to bone marrow chimaeras of wild-type mice reconstituted with CX3CR1-AHR bone marrow 9 led to earlier EAE onset, without affecting maximal scores and disease recovery (Extended Data Fig. 1g ). AHR deficiency in both CNS-resident and peripheral CX3CR1
+ cells accelerated EAE onset and impaired recovery (Extended Data Fig. 1h ). Collectively, these data suggest that microglial AHR limits EAE.
NF-κB controls microglial responses during EAE 8 , and AHR can limit NF-κB activation in a SOCS2-dependent manner 10, 11 . The deletion of microglial AHR decreased Socs2 expression and increased NF-κB p65 nuclear localization in spinal cord Iba-1 + myeloid cells during EAE (Fig. 1d, e) . Moreover, AHR deletion led to the upregulation of transcripts associated with microglial activation (Apoe, Ddit4 and B2m), inflammation and neurodegeneration (Ccl2, Nos2, Il1b and Il23a) 8, 12 ( Fig. 1f, g ).
Microglia modulate astrocyte phenotype and function 13 . Indeed, microglial AHR deletion upregulated the expression of genes in astrocytes associated with inflammation and neurodegeneration, such as Ccl2, Il1b and Nos2 (Fig. 2a, b) . Bioinformatic analyses aimed to identify candidate cause and effect relationships between dysregulated transcriptional responses in microglia and astrocytes identified two transcriptional modules in astrocytes, potentially controlled by microglia-produced Tgfa and Vegfb during EAE (Extended Data Fig. 2a and Fig. 2c ). Similar microglial Vegfb expression levels were detected throughout the CNS during EAE; Tgfa expression was slightly decreased in spinal cord microglia (Extended Data Fig. 2b ).
Microglial AHR deletion decreased Tgfa and increased Vegfb expression during EAE (Fig. 2d) . AHR regulates gene expression by direct interactions with target DNA regions, and also by controlling other transcription factors such as NF-κB 14, 15 . We identified AHR and NF-κB responsive elements (XREs and NREs, respectively) in the Veg fb and Tgfa promoters (Extended Data  Fig. 2c ). AHR deletion increased NF-κB p65 recruitment to NREs in the Vegfb promoter in microglia during EAE (Extended Data  Fig. 2d ). NF-κB p65 transactivated the Vegfb promoter in reporter assays; AHR suppressed this transactivation as well as Veg fb promoter basal activity (Extended Data Fig. 2e ). AHR was also Fig. 2 | AHR-regulated microglial TGFα and VEGF-B control astrocytes during EAE. a, Heat map of 14,823 genes (detected at 0.1 level in at least two of three samples) expressed in astrocytes from control and CX3CR1-AHR mice. Gene expression is row-centred log 2 -transformed and saturated at −0.5 and +0.5 levels for visualization satisfying an FDR < 0.1. n = 3 independent biological samples per group. b, mRNA expression determined by qPCR in control and CX3CR1-AHR EAE mice (n = 5 per group). c, Network diagram of differentially regulated genes in astrocytes and their predicted upstream regulators in microglia (n = 3 independent samples per group). d, Microglial mRNA expression determined by qPCR in control and CX3CR1-AHR EAE mice. Data are representative of two independent experiments with n = 6 control and n = 8 (Vegfb) or n = 6 (Tgfa) CX3CR1-AHR mice per group. e, Effect of MCM and blocking antibodies to TGFα and VEGF-B on gene expression in primary astrocytes determined by qPCR after 24 h. Data are representative of three independent experiments with three biological replicates. f, g, EAE in C57Bl/6J mice injected with lentiviral knockdown constructs targeting Tgfa, Vegfb or control in microglia (f), or Erbb1 (also known as Egfr), Flt1 or control in astrocytes (g). Data are representative of two independent experiments with n = 5 mice per group. Data in b, e-g are mean ± s.e.m. P values were determined by two-sided Student's t-test (b, d), one-way ANOVA followed by Tukey's post-hoc test (e) or two-way ANOVA (f, g). NS, not significant.
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recruited to XREs in the Tgfa promoter in microglia (Extended Data Fig. 2f ) and transactivated the Tgfa promoter in reporter studies (Extended Data Fig. 2g ). These findings suggest that AHR regulates microglial Tgfa and Vegfb expression through its direct effects on the Tgfa and Vegfb promoters, and through its ability to limit NF-κB activation.
We then analysed the effects of microglial TGFα and VEGF-B on astrocytes. Microglial AHR inhibition decreased Tgfa and increased Vegfb expression (Extended Data Fig. 3a) , and it boosted pro-inflammatory Ccl2 and neurotoxic Nos2 expression induced in astrocytes by microglial supernatants (Extended Data Fig. 3b-f ). Antibody blockade showed that TGFα and VEGF-B mediated these effects with a relative dominance of TGFα suppressive effects (Fig. 2e) . Recombinant TGFα decreased pro-inflammatory chemokine (Ccl2 and Csf2) and cytokine (Il6) expression induced in mouse astrocytes by TNF and IL-1β, whereas it enhanced Il10 expression (Extended Data Fig. 3g) . Conversely, VEGF-B boosted Ccl2, Csf2 and Nos2 expression in astrocytes. Similarly, VEGF-B pretreatment enhanced the toxicity of astrocyte-conditioned medium (ACM) towards neurons and oligodendrocytes; TGFα reduced this toxicity (Extended Data Fig. 3h,i) . VEGF-B pretreatment also enhanced pro-inflammatory monocyte recruitment and microglia activation by ACM; these activities were inhibited by TGFα (Extended Data Fig. 3j,k) . These data suggest that TGFα and VEGF-B control astrocyte functions that contribute to CNS pathology.
To investigate the interaction between microglia and astrocytes in vivo, we knocked down Tgfa and Vegfb expression in microglia using lentivirus-delivered short-hairpin RNAs (shRNAs) expressed under the control of the Itgam (encoding CD11b) promoter. The knockdown did not affect astrocyte numbers or morphology, nor Tgfa and Vegfb expression in CNS-infiltrating monocytes (Extended Data Fig. 4a-f ). Microglial Tgfa knockdown worsened EAE, whereas Vegfb knockdown ameliorated it (Fig. 2f ). Similar observations were made when the TGFα or VEGF-B receptors ErbB1 or FLT-1, respectively, were knocked down in astrocytes (Fig. 2g, Extended Data Fig. 4a, b, e, g ). Of note, VEGF-B administration did not induce demyelination in naive mice (Extended Data Fig. 4h ), suggesting that VEGF-B synergizes with other factors to boost EAE pathology. Moreover, the knockdown of Tgfa and Vegfb in astrocytes or of their receptors in microglia did not affect EAE (Extended Data Fig. 5 ), supporting a microglia to astrocyte directionality in their effects.
Transcriptional analyses suggested that TGFα-ErbB1 and VEGF-B-FLT-1 regulate NF-κB in astrocytes (Extended Data Fig. 6a-d) , known to drive their pathogenic activities during CNS inflammation 10, [16] [17] [18] . Indeed, NF-κB signalling in astrocytes was increased after microglial AHR deletion (Extended Data 2a). Interestingly, VEGF-B boosted astrocytic NF-κB activation; this boost was inhibited by TGFα (Extended Data Fig. 6e ). Moreover, NF-κB blockade suppressed the increase in pro-inflammatory gene expression induced by VEGF-B in astrocytes (Extended Data Fig. 6f, g ). Collectively, these findings suggest that by controlling NF-κB signalling, VEGF-B and TGFα modulate astrocyte pathogenic activities.
The microbial metabolism of dietary tryptophan (Trp) generates AHR agonists such as I3S, which limits astrocyte pathogenic activities and EAE development 10, 19, 20 . To investigate the role of microglial AHR in the control of CNS inflammation by dietary Trp meta bolites, we subjected control and CX3CR1-AHR mice to a Trp-depleted diet (TDD) initiated 21 days after EAE induction. Trp depletion interfered with disease recovery in control mice (Fig. 3a) . Trp or I3S administration ameliorated EAE in control but not in CX3CR1-AHR TDD-fed mice (Fig. 3a) , suggesting that microglial AHR participates in EAE amelioration by Trp metabolites. In addition, a TDD initiated 14 days after EAE induction worsened disease in control mice and also in mice with AHR-deficient microglia or astrocytes (Extended Data Fig. 7a-c ), suggesting that Trp metabolites limit CNS inflammation via both microglial and astrocytic AHR. Indeed, I3S administration initiated 14 days after EAE induction ameliorated disease via AHR in astrocytes and microglia (Extended Data Fig. 7b, c) . Similar results were obtained when AHR was knocked down in astrocytes or microglia (Extended Data Fig. 7d-g ). Collectively, these findings suggest that microglial AHR deletion Letter reSeArCH renders astrocytes unresponsive to the anti-inflammatory effects of AHR ligands at later EAE stages. The transcriptional response of microglia in TDD-fed control mice resembled that of AHR-deficient microglia (Fig. 3b, c) . Indeed, the microglial expression of Ahr and its target gene Cyp1b1 was suppressed in TDD-fed and CX3CR1-AHR mice, and could be restored by Trp or I3S supplementation in control but not in CX3CR1-AHR mice (Fig. 3d) . Moreover, dietary Trp metabolites promoted Socs2 expression, which mediates NF-κB regulation by AHR 10, 11 and suppressed the microglial expression of NF-κB dependent transcripts such as Tnf (also known as Tnfa) in an AHR-dependent manner ( Fig. 3b and Extended Fig. Data 8a) . In addition, dietary Trp metabolites also regulated microglial Tgfa and Vegfb expression via AHR (Fig. 3e) . Accordingly, astrocytes from CX3CR1-AHR and TDD-treated control mice showed increased expression of genes linked to EAE pathogenesis such as Ccl2 and Nos2 (Extended Data Fig. 8b and Fig. 3f ). Collectively, these findings suggest that dietary Trp metabolites such as I3S limit NF-κB driven pro-inflammatory programs in microglia and suppress their ability to promote proinflammatory activities in astrocytes.
We validated our observations using human samples. AHR was activated by I3S and inhibited by the antagonist CH223191 in primary human microglia, as indicated by the expression of AHR and its target CYP1B1 (Fig. 4a) . Microglial AHR activation suppressed pro-inflammatory and neurotoxic gene expression (TNF, IL6, IL12A and NOS2) and boosted anti-inflammatory IL10 expression; AHR activation also promoted TGFA and suppressed VEGFB expression in human microglia (Fig. 4b, c) . More importantly, TGFα and VEGF-B suppressed and Letter reSeArCH boosted, respectively, pro-inflammatory gene expression in primary human astrocytes (Fig. 4d) .
Finally, we analysed AHR, TGFα and VEGF-B expression on brain samples from patients with MS. We detected AHR, TGFα and VEGF-B expression in CD14 + cells (microglia and recruited monocytes) in the normally appearing white matter (NAWM), demyelinated active and chronic multiple sclerosis (MS) lesions; the highest AHR, VEGF-B and TGFα expression was detected in CD14 + cells in MS active lesions (Fig. 4e, f and Extended Data Fig. 8c ). VEGF-B and AHR expression in chronic MS lesions were comparable to their levels in NAWM, whereas TGFα expression was decreased to levels below those detected in the NAWM, resulting in a higher VEGF-B/TGFα ratio than in NAWM ( Fig. 4g and Extended Data Fig. 8d ). These findings suggest that VEGF-B and TGFα participate in the control of astrocytes by microglia in humans and contribute to MS pathogenesis.
In summary, we found that AHR-controlled microglial VEGF-B and TGFα regulate astrocyte pathogenic activities during EAE. VEGF-A promotes CNS pathology by several mechanisms including angiogenesis induction 21 , and microglia 22 and T cell 23 stimulation, but less is known about VEGF-B, which does not promote angiogenesis in the CNS 24 and shows neuroprotective effects in some models 25 . Our data suggest that FLT-1 activation in astrocytes by VEGF-B produced by microglia and other sources 26 promotes CNS inflammation, identifying VEGF-B-FLT-1 signalling inhibitors as candidate therapeutics for CNS inflammation. Conversely, TGFα induces astrogliosis and neuroprotective factor production, and increases neuronal survival and axonal growth in multiple contexts, including models of spinal cord injury 27, 28 . Indeed, based on the promotion of axon regeneration by reactive astrocytes in spinal cord injury models 29 , it is tempting to speculate that microglial TGFα promotes these beneficial astrocyte activities. Future studies should address whether the control of TGFα-ErbB1 signalling via AHR contributes to the beneficial effects of commensal bacteria on spinal cord injury 30 . In conclusion, our findings define a gut-brain axis by which metabolites of dietary Trp controlled by the commensal flora act directly on CNS-resident microglia and astrocytes 10 to limit inflammation and neurodegeneration via AHR.
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MEthodS
Animals. C57BL/6J mice were obtained from the Jackson Laboratory and were all female. Cx3cr1 creERT2 mice 8 were a gift from S. Jung and were bred to Ahr fl/fl mice. To delete microglial AHR, 4-5-week-old mice were injected subcutaneously with 4 mg tamoxifen (Sigma) in 200 µl warm corn oil at two time points 48 h apart. Cx3cr1 creERT2 -negative Ahr fl/fl mice were used as controls. Four weeks later, EAE was induced. To delete AHR in all CX3CR1-expressing cells, control and CX3CR1-AHR mice were gavaged weekly with tamoxifen starting from 5 weeks of age. EAE was induced and weekly tamoxifen gavages were continued after EAE induction.
Bone marrow chimaera were generated as previously described to minimize irradiation-induced artefacts 31, 32 . In brief, 7-week-old wild-type recipient mice were lethally radiated with a dose of 9.5 Gy. One day later, mice were administered 5 × 10 6 bone marrow cells isolated from donor femora and tibiae by intravenous injection. Donors were Cx3cr1 cre -negative Ahr fl/fl and Cx3cr1 cre -positive Ahr fl/fl mice. Bone marrow recipients were then rested for 3 weeks and thereafter treated with weekly tamoxifen gavages for another 3 weeks; after a total of 6 weeks, EAE was induced as described below. Tamoxifen administration was continued weekly during EAE. All mice were on the C57BL/6 background and were kept in a pathogenfree facility at the Harvard Institutes of Medicine. All experiments were carried out in accordance with guidelines prescribed by the Institutional Animal Care and Use Committee (IACUC) at Harvard Medical School. EAE induction and treatment. EAE was induced in 8-week-old mice by subcutaneous immunization with 150 µg myelin oligodendrocyte glycoprotein (MOG 35-55 ) peptide (Genemed Synthesis Inc.) emulsified in complete Freund's adjuvant (CFA, Difco Laboratories) per mouse, followed by administration of 200 ng pertussis toxin (PTX, List Biological Laboratories, Inc.) on days 0 and 2 as described 10 . Clinical signs of EAE were assessed as follows: 0, no signs of disease; 1, loss of tone in the tail; 2, hind limb paresis; 3, hind limb paralysis; 4, tetraplegia; 5, moribund. All agents were purchased from Sigma-Aldrich. Isolation of cells from adult mouse CNS. Mononuclear cells were isolated from the CNS as previously described, and astrocytes, monocytes, and microglia were sorted as described before 10, 16, 17 . Isolated CNS cells were stained with fluorochrome-conjugated antibodies to CD11b (M1/70, 1:100), CD45 (90, 1:100), Ly6C1 (HK1.4, 1:100), CD105 (N418, 1:100), CD140a (APA5, 1:100), CD11c (N418, 1:100), F4/80 (BM8, 1:50), O4 (O4, Miltenyi Biotec, 1:10), and CD19 (eBio1D3, 1:100 lo after the exclusion of lymphocytes, microglia, oligodendrocytes, and monocytes. Flow cytometry staining and acquisition. Mononuclear cell suspensions were prepared as previously described 10, 16, 17 . Antibodies for flow cytometry were purchased from eBioscience or BD Pharmingen and used at a concentration of 1:100 unless recommended otherwise by the manufacturer. Mouse AHR antibody (IC6697G) and mouse FLT-1 antibody (FAB4711A) were from R&D Systems, VEGF-B (RM0008-6E72) and TGFα (MF9) from Novus Biologicals, EGFR (D38B1) and p-p65 (93H1) from Cell Signaling. Cells were then analysed on a LSRII or MACSQuant flow cytometer (BD Biosciences and Miltenyi Biotec, respectively). As outlined in the individual figures, T-helper 1 (T H 1) cells were defined as 
RNA-seq.
Mice were euthanized at day 25 after disease induction and astrocytes isolated as described above. RNA was sequenced using the strand-specific TruSeq protocol. High coverage (>50 M) strand-specific paired-end 76-base-pair (bp) reads were aligned to the mm10/GRCm38 mouse reference genome using TopHat v2.0.11 33 . Gene expression levels were estimated for 38922 GenCode Release M2 (GRCm38.p2) mouse gene annotations using Cuffquant and Cuffnorm v2.2.1 quartile normalized FPKMs 33 . nCounter gene expression. In total, 50 ng of total RNA was hybridized with reporter and capture probes in custom-made astrocyte-targeted nCounter Gene Expression code set according to manufacturer's instructions (NanoString Technologies). Data were analysed using nSolver Analysis software. qPCR. RNA was extracted using the RNAeasy kit (Qiagen), cDNA was prepared and used for qPCR with the results normalized to Gapdh. All primers and probes were from Applied Biosystems. Mouse: ) for 15 min, and dispersed to single-cell level by passing through a cell strainer (70 µm). The cell suspension was then cultured at 37 °C in humidified 5% CO 2 , 95% air on poly-l-lysine (Sigma) precoated 75 cm 2 cell culture flasks. Medium was replaced every 4-5 days. After 7-10 days, cells reached confluence and astrocytes and microglia were isolated by mild trypsinization with Trypsin-EDTA (0.06%) as previously described 10, 16, 17 . Cells were >95% astrocytes as determined by staining with GFAP or GLAST, with less than 5% contamination of CD11b + microglia cells (not shown). Conversely, microglia cultures stained CD11b + CD45 lo Ly6C1 lo >95%. After the isolation procedure, cells were further plated as required for the specific experiments. Concentrations of agents were 100 ng ml −1 for LPS (Sigma), 50 µg ml −1 for poly(I:C), 100 ng ml −1 for IL-1β, 50 ng ml −1 for TNF, 0.1 ng ml −1 TGFα, 10 ng ml
VEGF-B (all R&D Systems), 50 µg ml −1 3-indoxyl-sulfate (Sigma), 100 nM NF-κB Blocker Bengamide B (Tocris). Unless otherwise indicated, RNA was isolated 24 h after start of treatment. For western blot analysis, cells were pretreated with I3S or vehicle for 24 h, thereafter LPS was added and protein prepared after 2 h. Plasmids. Constructs encoding p65, AHR, pTgfa-Luc, pVegfb-Luc, as well as pTK-Renilla were obtained from Addgene. The pLenti-GFAP-EGFP-mir30-shAct1 vector was a gift from G.-X. Zhang
34
. The pLenti-CD11b-EGFP-mir30-shRNA was also provided by G.-X. Zhang, who generated it by exchanging the Gfap promoter with the Cd11b (also known as Itgam) promoter. In vivo knockdown with shRNA lentivirus. shRNA sequences against Ahr, Tgfa, Vegfb, Erbb1 or Flt1 and a non-targeting control shRNA were cloned into pLenti-GFAP-EGFP-mir30-shRNA or pLenti-CD11b-EGFP-mir30-shRNA using the following validated shRNA sequence against Ahr ( 5′-CCGGCATCGACATAAC GGACGAAATCTCGAGATTTCGTCCGTTATGTCGATGTTT TTG-3′), Tgfa (5′-CCGGTCGTCAGGATGCGTGTCTTATCTCGAGATAAGACACGCATCC TGACGATTTTTG-3′), Vegfb (5′-CCGGGCCAATGTGAATGCAGACCAA CTCGAGTTG GTCTGCATTCACATTGGCTTTTTG-3′), Erbb1 (5′-CCGGGCTGGATGATAGATGCTGATACTCGAGTATCAGCATCTATCATCC AGCTTTTTG-3′) or Flt1 (5′-CCGGCGTGACCTTTAATCGTGCTTTCTCG AGAAAGCACGATTAAAGGTCACGTTTTT-3′) as described 16 . Lentivirus particles were generated by transfecting HEK-293FT cells (Invitrogen) with the pLenti-GFAP-EGFP-mir30-shRNA or pLenti-CD11b-EGFP-mir30-shRNA vector and the ViraPower Packaging mix (helper plasmids pLP1, pLP2, pLP/VSV-G, Invitrogen). Supernatants were collected, filtered through a 0.45-µm PVDF filter, and concentrated overnight with the Lenti-X concentrator kit (Clontech). The viral titre was determined using the Lenti-X qRT-PCR titration kit (Clontech). For in vivo knockdown, immunized mice were anaesthetized at indicated time points, positioned in a Kopf Stereotaxic Alignment System and injected with 10 7 IU of respective virus using a Hamilton syringe 0.44 mm posterior to the bregma, 1.0 mm lateral to it and 2.3 mm below the skull surface. The injection system was retracted slowly, skin incisions closed carefully by surgical sutures, mice allowed to wake up in a cage pre-warmed with a red light and mice checked twice daily thereafter. Assessment of toxicity towards neurons and oligodendrocytes. N2A neuronal cells (ATCC CCL-131, ATCC) or mouse oligodendrocytes (Celprogen, 11004-02) were grown in 96-well plates and pre-activated with mouse IFNγ (100 ng ml 
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Microglia polarization assays. Wild-type microglia were co-cultured with astrocytes pre-treated with TGFα or VEGF-B and extensively washed. After 24 h, microglia were re-isolated, RNA was isolated, transcribed and subjected to qPCR analysis. Subcellular fractionation and immunoblot analysis. In vitro microglia cultures were treated as indicated in specific experiments, subcellular fractions generated using Cell Fractionation kit (Cell Signaling) and 10 µg of nuclear and cytoplasmic fractions were separated by 4-12% Bis-Tris Nupage gels (Invitrogen) and transferred onto PVDF membranes (Millipore). As primary antibodies rabbit anti-GAPDH monoclonal antibody (14C10, Cell Signaling), anti-histone H3 rabbit polyclonal antibody (EMD Millipore), anti-NF-κB p65 rabbit monoclonal antibody (D14E12, Cell Signaling) were used, followed by goat anti-rabbit IgG horseradish peroxidase (HRP)-linked antibody (7074S, Cell Signaling). All antibodies were used at a dilution of 1:1,000. Blots were developed using the SuperSignal West Femto Maximum sensitivity kit (Thermo Scientific/Life Technologies). Data quantification was done using Image J software 1.48v (NIH) and specific signals normalized to GAPDH (cytoplasm) or histone 3 (nucleus). Chromatin immunoprecipitation. Cells were cross-linked with 1% paraformaldehyde and lysed with 350 µl lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1) containing 1× protease inhibitor cocktail (Roche Molecular Biochemicals). Chromatin was sheared by sonication and supernatants were collected after centrifugation and diluted in chromatin immunoprecipitation incubation buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH 8.0). Ten micrograms of antibody was prebound for 6 h to protein A-and protein G-Dynal magnetic beads (Invitrogen) and washed three times with PBS plus 1% bovine serum albumin (BSA), and then added to the diluted chromatin and immunoprecipitated rotating overnight. The magnetic bead-chromatin complexes were then washed three times in RIPA buffer (50 mM HEPES (pH 7.6), 1 mM EDTA, 0.7% sodium deoxycholate, 1% NP-40, 0.5 M LiCl) and then twice with Tris-EDTA (TE) buffer. Immunoprecipitated chromatin was then extracted with 1% SDS, 0.1 M NaHCO 3 and heated at 65 °C for 8 h to reverse the paraformaldehyde cross-linking. DNA fragments were purified with a QIAquick DNA purification kit (Qiagen) and analysed using the SYBR Green real-time PCR kit (Takara Bio Inc.). Anti-AHR (BML-SA210, Enzo Life Sciences), anti-NF-κB p65 (D14E12) XP rabbit monoclonal antibody (8242, Cell Signaling Technology), and recombinant IgG isotype control were used as indicated in specific experiments. The following primer pairs were used: VEGFB_NFKb1: forward 5′-TCTGTGGCATAGAAACCCAAAG-3′, reverse 5′-ACCCTAAGTCACTGGCTGTC-3′, VEGFB_AHR1: forward 5′-ACCTTCTTCACAGGACAGCC-3′ and reverse 5′-AGTCTCCGAACTCTG GTGTC-3′, VEGFB_AHR2: 5′-GAGTTAACTGCAATTCCTTCACA-3′ and reverse 5′-CTGGAGGGTGGTGCTGAAG-3′, VEGFB_ NFK2/AHR3: forward 5′-T TCAT TGGTCCTCTCCCTGC-3′ and reverse 5′-CAGGGGAAA GGGGACACAC-3′, VEGFB_AHR3 + 4: forward 5′-GTCCCCTTTCCC CTGCAG-3′ and reverse 5′-AGAGGCTCATGTGACCTAAACA-3′, TGFA_AHR1: forward 5′-GCCAAGGGAGCATGAACTAG-3′ and reverse 5′-GATG CTCAAAGTTTCAGAGTTGA-3′, TGFA_AHR2: forward 5′-AGGAGAGGG GTCAGTCTGAT-3′ and reverse 5′-AGAGGGAAACACAAG AAGGGA-3′, TGFA_AHR3: forward 5′-GACTCAGAGTGGGGCCAG-3′ and reverse 5′-GAGTCGCTCAGGATCCAGTC-3′. Human primary astrocytes and microglia. Human fetal astrocytes and microglia were isolated as previously described 16 ) with or without 3-indoxyl-sulfate (50 µM, Sigma) or untreated (control) as indicated in the respective figures. After 24 h, total RNA was isolated, transcribed and subjected to qPCR. Immunohistochemistry and astrocyte morphometry. Mice were anaesthetized (intraperitoneal injection of 100 mg ketamine and 5 mg xylazine per kg body weight) and transcardially perfused with PBS followed by 4% paraformaldehyde in PBS. CNS and other organs were post-fixed for 4-6 h at 4 °C, washed in PBS and incubated in 30% sucrose in PBS at 4 °C until fully enriched. Samples were embedded in OCT (Tissue-Tek) for frozen sectioning on a cryostat (Leica). All the stainings were performed on 30 µm thick transversal spinal cord sections. The sections were permeabilized in blocking solution (0.5% Triton-X 100, 5% BSA, 5% normal donkey serum and 0.1% NaN 3 in PBS) for 1 h at room temperature. Primary antibodies were dissolved in blocking solution and incubated overnight at 4 °C with the following primary antibodies: Lys310-acetyl p65 (ab52175, Abcam), SOX9 (AF3075, R&D, 1:200), GFAP (RBK037, Zytomed, 1:5,000), IBA-1 (ab178846, Abcam, 1:500), DAPI (1:5,000). Conjugated secondary antibodies used were donkey anti-rabbit Alexa Fluor 647 (Invitrogen A-31573), donkey anti-rabbit Alexa Fluor 568 (Invitrogen A-10042) and donkey anti-goat Alexa Fluor 488 (Life Technologies A11055) for 2 h at room temperature. TUNEL staining was performed using the In situ Cell Death Detection Kit, TMR red (Roche, 12156792910). Slices were mounted with ProLong Diamond Antifade Mountant (Life Technologies, P36961).
For immunohistochemistry with DAB, after harvesting as described above, spinal cords were cut transversally, embedded in paraffin blocks, cut in 4 µm thick slices in a microtome, cooked 40 min in citrate buffer at 98 °C using a vapour cooker for antigen retrieval, incubated one hour using 10% normal goat serum (SouthernBiotech, 0060-01) in PBS as blocking buffer, incubated overnight at 4 °C using primary rat anti-Mac3 antibody (BD-Pharmingen Biosciences, 553322) diluted 1:200 in blocking buffer, incubated biotin-conjugated goat anti-rat antibody (SouthernBiotech, 3050-08) 45 min at room temperature diluted 1:1,000 in blocking buffer as secondary antibody and finally incubated for 45 min at room temperature with streptavidin-HRP (SouthernBiotech, 7100-05) diluted 1:1,000 in PBS. The samples were washed four times in PBS plus 0.1% Triton X-100 between each step. The DAB reaction was run for 5 min using the EnVision Flex kit (Dako). Slides were counterstained with Gill's Hematoxilin, dehydrated trough an ethanol and xylol gradient and mounted with in vitro-Clud (R. Langenbrinck, 04-0001) using a Leica CV5030 system. All images were taken with a Keyence BZ-9000 microscope. For astrocyte reconstruction a Leica Confocal SP8 microscope was used. The Imaris 9.0.2 Software was used to reconstruct and get the morphometry data. In vivo demyelination assay. Naive mice were anaesthesized and injected stereotaxically into the corpus callosum (1.4 anterior, 1.0 lateral, 2.1 mm deep) with 2 µl of Lysolecithin (1% (w/v), Sigma), VEGF-B (500 ng, R&D Systems), or PBS. Mice were euthanized 6 days later and subjected to myelin staining as described below. MS tissue and immunofluorescence. Brain tissue was obtained from untreated individuals with clinically diagnosed and neuropathologically confirmed MS, and healthy controls as previously described 10, 16 . All MS individuals and controls, or their next of kin, had given informed consent for autopsy and use of their brain tissue for research purposes. All the procedures were performed in accordance with local Institutional Review Board guidelines. MS samples were processed and immunostained as previously described 2 . In brief, sections were thawed, fixed, washed and blocked with donkey serum 10%. Sections were then incubated overnight at 4 °C with antibodies against AHR (rabbit anti-AHR, Enzo Life Sciences), CD14 (mouse anti-human CD14, 325602, Biolegend), TGFα (ab112030, Abcam) and VEGF-B (ab185696, Abcam). After washes the samples were incubated at room temperature for 40 min with the secondary antibodies (donkey anti rabbit RRX and donkey anti mouse Alexa 488, Jackson ImmunoResearch). Imaging was performed using a Leica SP5 confocal microscope and the Leica LAS AF software. Images were processed using Adobe Photoshop CS2. For imaging analysis, all the data were acquired using the same settings, which were originally standardized on NAWM sections. The degree of co-localization of CD14 with AHR, TGFα, and VEGF-B was determined using the Volocity software from Perkin Elmer. The overlap coefficient is expressed in percentage where 100% represents the maximum degree of co-localization and 0% denotes no co-localization. RNA-seq data processing. RNA-Seq data was analysed using DESeq2. Gene expression with 0 counts and low expression were removed before differential analysis. Low expressed were filtered out by the DESeq independent filtering, which removes genes in the lowest 40% quantile of mean normalized counts. Differential genes were selected with FDR < 0.1. Heat maps. Heat maps were generated with the Gene-E program, and the z-scores were calculated for each gene row using the mean expression of biological replicates. tSNE plots. tSNE plot was created using R and the Rtsne package, with parameters perplexity = 1, max iterations = 3,000. The mean average of replicates and the top 500 ranked genes for TDD + Trp and TDD in control mice (n = 3) was taken and the final plot was generated using ggplot. Ingenuity pathway analysis. To determine significant pathways, differentially expressed genes that passed FDR < 0.1 were uploaded and analysed using Ingenuity Pathway Analysis (IPA) tool. P values of canonical signalling pathways were calculated using Fischer's exact test. The NF-κB network diagram was generated using IPA. Network diagram. Network diagram for protein-protein interactions was visualized with NetworkAnalyst, (http://www.networkanalyst.ca), using the STRING Interactome database (confidence score cutoff = 900). Minimum network displaying interacting mediators and molecules were colour-coded based on associated pathways for VEGF-B and TGFα. Statistical analysis. Statistical analyses were performed with Prism software (GraphPad), using the statistical tests indicated in the individual figure legends. No samples were excluded. The investigators were blinded as to the treatment Letter reSeArCH 
Extended Data Fig. 1 | Contribution of AHR in CNS resident and  infiltrating immune cells during EAE. a, qPCR of + microglia in spinal cord sections of control and CX3CR1-AHR mice as in c. For the positive control, slides were cooked at 98 °C in citrate buffer during 60 min using a vapour cooker. Solid arrows show TUNEL positive microglia. Representative of n = 5 independent experiments. e, Number of CNS-infiltrating (top) and splenic T cells (bottom), and splenic pro-inflammatory monocytes (bottom) as determined by flow cytometry. n = 5 samples per group for CNS, n = 4 samples per group for spleen. f, Proliferation assay from splenocytes isolated on day 28 of the experiment. n = 4 biologically independent samples per group, representative of two independent experiments. g, Bone marrow chimaera were generated using wild-type mice irradiated as recipients, reconstituted with control or CX3CR1-AHR bone marrow. Recipients of bone marrow were then rested for 3 weeks and thereafter treated with weekly tamoxifen gavages (4 mg) for another 3 weeks; after a total of 6 weeks, EAE was induced and tamoxifen administration continued weekly during EAE. Left, flow cytometry analysis of AHR expression in microglia and monocytes 21 days after EAE induction. Thin line depicts isotype control, thick line denotes AHR staining, and numbers indicate the percentage of AHR-positive cells. Representative of stainings of n = 3 independent mice per group. Right, EAE clinical course in bone marrow chimaera mice. n = 4 mice per group. h, Control and CX3CR1-AHR mice were treated with oral tamoxifen weekly starting from 5 weeks of age. EAE was induced at 8 weeks under continuation of weekly tamoxifen administration. Left, intracellular FACS staining for AHR in microglia and monocytes from at day 21 of EAE. Representative of stainings of n = 3 independent mice per group. Right, clinical course of control and CX3CR1-AHR bone marrow chimaera mice. Data in a, c, e-h are mean ± s.e.m. of n = 4 mice per group. P values were determined by two-sided Student's t-test (a, c, e) or two-way ANOVA (g, h).
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Extended Data Fig. 3 | TGFα and VEGF-B are regulated by AHR in  highly purified astrocytes and microglia. a, b , Mouse microglia were activated with lipopolysaccharide (LPS) in the presence or absence of the AHR inhibitor CH223191. After 24 h, activation medium was removed and substituted with fresh medium after extensive washes. Then 48 h later, microglia conditioned medium (MCM) was collected and applied to cultures of primary astrocytes. a, Gene expression in microglia 24 h after activation in the presence or absence of CH223191. b, Gene expression in astrocytes after 24 h exposure to MCM. Data are representative of two independent experiments with three biological replicates. c, Representative FACS stainings for CD11b and CD45 in primary astrocyte and microglia cultures. Numbers indicate percentages in respective gate. Data are representative of three independent experiments. d, Representative FACS stainings for GFAP and GLAST in astrocyte cultures as in b. Data are representative of three independent experiments. e, f, qPCR analysis of mRNA expression in astrocyte and microglia cultures. n = 4 independent cultures. Data are representative of two independent experiments with four biological replicates. g, Effect of TGFα and VEGF-B on gene expression in primary astrocytes activated with TNF and IL-1β, determined by pPCR after 24 h. Data are representative of three independent experiments with three biological replicates. h, i, Primary mouse astrocytes were activated with TNF and IL-1β and treated with TGFα or VEGF-B. After 24 h later, culture medium was substituted by fresh medium after extensive washes. Then 48 h later, ACM was added to mouse neurons (h) and oligodendrocytes (i) in culture, and cytotoxicity was determined by quantifying lactate dehydrogenase (LDH) release after 24 h. n = 3 biological replicates. Data are representative of two independent experiments. j, CD11b + Ly6C hi monocyte migration assay performed using ACM from astrocytes activated in the presence of TGFα or VEGF-B. n = 4 biological replicates. Data are representative of two independent experiments. k, qPCR analysis of Nos2 expression in microglia co-cultured with astrocytes activated in the presence of TGFα or VEGF-B. n = 3 biological replicates. Data are representative of two independent experiments. Data in b, e-k are mean ± s.e.m. P values were determined by two-sided Student's t-test (b, e, f) or one-way ANOVA followed by Tukey's post-hoc test (g-k). + astrocytes in spinal cord sections as in a, and quantification of dendrite length, branches, volume, terminal points, and segments of n = 4 mice per group. c, d, qPCR analysis of Tgfa and Vegfb expression in sorted CNS-infiltrating inflammatory monocytes (c) and microglia (d) from mice injected with pCD11b-shControl, pCD11b-shTgfa, and pCD11b-shVegfb 7 days after EAE induction. Representative of two independent experiments with three biological replicates. e, qPCR analysis of Erbb1 and Flt1 expression in mice injected with pGFAP-shControl, pGFAP-shErbb1, and pCD11b-shFlt1 7 days after EAE induction. Representative of two independent experiments with three biological replicates. f, Left, flow cytometry analysis of VEGF-B and TGFα expression in microglia from mice injected with pCD11b-shControl, pCD11b-shTgfa, and pCD11b-shVegfb 7 days after EAE induction. Right, quantification of VEGF-B-and TGFα-positive microglia in n = 5 mice per group. Representative of two independent experiments with five biological replicates. g, Left, flow cytometry analysis of FLT-1 and ErbB1 expression in astrocytes from mice injected with pGFAP-shControl, pGFAP-shErbb1, and pCD11b-shFlt1 7 days after EAE induction. Right, quantification of FLT-1 and ErbB1-positive microglia in n = 5 mice per group. Representative of two independent experiments with five biological replicates. h, Naive mice were injected with lysolecithin, VEGF-B, or PBS into the corpus callosum by stereotaxic injection and 6 days later, brains were analysed by myelin staining. Representative of two independent experiments with five biological replicates. Data are mean ± s.e.m. P values were determined one-way ANOVA followed by Tukey's post-hoc test (a-h). 
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section) For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
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